慢性髓系白血病初诊患者M-BCR/ABL与M-BCR/ABL融合基因转录子共表达的临床意义  

Effect of Co-expressing M-bcr/abl and m-bcr/abl Fusion Gene Transcripts on the Clinical Features of Patients with Chronic Myelogenous Leukemia at Diagnosis

作　　者：孟文彤[1] 刘霆[1] 李建军[1] 史青[2] 余江[2] 崔旭[1] 吴俣[1] 向兵 

机构地区：[1]四川大学华西医院血液科,成都610041 [2]四川大学华西医院实验医学科

出　　处：《四川大学学报（医学版）》2006年第1期97-100,共4页Journal of Sichuan University(Medical Sciences)

摘　　要：目的探讨慢性髓系白血病(CML)初诊患者M-BCR/ABL与M-BCR/ABL融合基因转录子共表达的临床意义。方法对111例初诊CML患者抽取骨髓,分离单个核细胞后,使用巢式PCR检测M-BCR/ABL融合基因转录子的表达。结果111例CML患者M-BCR/ABL和M-BCR/ABL共表达率为51.4%;共表达与单M-BCR/ABL阳性的初诊CML患者相比在血红蛋白浓度、白细胞数、中性粒细胞碱性磷酸酶(NAP)比例及积分、PH染色体比例和肝脾肿大均无差异,仅血小板数差异有统计学意义(P<0.05)。B3A2型共表达患者血小板数比单M-BCR/ABL阳性患者高(P<0.05);B2A2型共表达和单表达患者比较差异均无统计学意义。有2例患者阴茎异常勃起,均为M-BCR/ABL阴性CML患者。结论共表达M-BCR/ABL的B3A2型初诊CML患者易有血小板数增高;共表达M-BCR/ABL对B2A2型初诊CML患者的临床表现无影响。Objective To study the effect of co-expressing M-bcr/abl and m-bcr/abl fusion gene transcripts on the clinical features of the patients with chronic myelogenous leukemia （CML） at diagnosis. Methods m-bcr/ abl fusion gene transcripts were detected by nested PCR. Results The percentage of the CML patients who co-expressed M-bcr/abl and m-bcr/abl was 51.4% at diagnosis. Comparison of the patients who co-expressed and those who expressed M-bcr/abl alone showed there was no difference in their hemoglobin concentrations, WBC counts, neutrophilic alkaline phosphatase （NAP） stains, Ph chromosomes and hepatosplenomegaly; however, significant difference in platelet count was seen. In the patients with b3a2 who co-expressed m-bcr/abl, an increased platelet count was noted, compared with that of patiets with M-bcr/abl alone. But in patients with b2a2, the two groups showed no difference in all clinical features. Two patients had priapism, their m-bcr/abl being negative. Conclusions CML patients who co-expressed b3a2 and m-bcr/abl showed a tendency to have an increased platelet count at diagnosis. Co-expressing m-bcr/abl has no the effect on the clinical features of CML patients with b2a2.

关 键 词：慢性髓细胞白血病 M-bcr/abl m-bcr/abl 共表达 

分 类 号：R733.7[医药卫生—肿瘤]